DYSPORT™ Clinical & Health Economics Outcomes Registry in Cervical Dystonia
NCT ID: NCT01314365
Last Updated: 2020-11-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
350 participants
OBSERVATIONAL
2011-04-30
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* If previously treated with a neurotoxin for CD, at least a 12-week interval must have elapsed between the last injection of Botulinum toxin A (BoNT-A) or Botulinum toxin B (BoNT-B) and the first dose of Dysport injected in this study
* Patient is able to comply with the protocol (e.g., can visit the clinic as required and can complete questionnaires/telephone interviews)
* Provision of written informed consent prior to enrollment
Exclusion Criteria
* Based on Investigator opinion, patients in whom previous BoNT-A or BoNT-B therapy has failed to produce a clinical response or produced an intolerable adverse reaction
* Anticipated concomitant treatment with BoNT for other than cervical dystonia
* Secondary cervical dystonia
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Study Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Dystonia Institute
Scottsdale, Arizona, United States
East Bay Physicians Medical Group
Berkeley, California, United States
Headache Center
Encinitas, California, United States
The Parkinson's & Movement Disorder Institute
Fountain Valley, California, United States
Neuro-Pain Medical Center
Fresno, California, United States
Coastal Neurological Medical Group, Inc.
La Jolla, California, United States
Valley Parkinson Clinic
Los Gatos, California, United States
Harvinder S. Birk
Redding, California, United States
Colorado Springs Neurological Associates
Colorado Springs, Colorado, United States
University of Colorado Denver
Denver, Colorado, United States
Georgetown University Hospital
Washington D.C., District of Columbia, United States
Neurology Offices of South Florida
Boca Raton, Florida, United States
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida, United States
Infinity Clinical Research, LLC
Hollywood, Florida, United States
University of Miami, Dept. of Movement Disorders Clinic
Miami, Florida, United States
Palm Beach Gardens Medical Center
North Palm Beach, Florida, United States
Emerald Coast Center for Neurological Disorders
Pensacola, Florida, United States
Parkinson's Treatment Center of SW Florida
Port Charlotte, Florida, United States
USF HealthParkinson's Disease and Movement Disorders Center
Tampa, Florida, United States
Cleveland Clinic Florida
Weston, Florida, United States
Elks Rehab Hospital - Movement Disorders Center
Boise, Idaho, United States
Rush University Medical Center Department of Neurological Sciences
Chicago, Illinois, United States
Kansas City Bone & Joint Clinic, PA Overland Park
Overland Park, Kansas, United States
Baptist Neurology Center - Lexington
Lexington, Kentucky, United States
The Neuro Medical Center
Baton Rouge, Louisiana, United States
The Parkinson's and Movement Disorders Center
Southfield, Michigan, United States
Rehabilitation Consultants, PA
Eagan, Minnesota, United States
Methodist Rehabilitation Center
Jackson, Mississippi, United States
University of Nevada School of Medicine
Reno, Nevada, United States
Empire Neurology PC, the MS Center of Northeastern New York
Latham, New York, United States
Raleigh Neurology Associates
Raleigh, North Carolina, United States
Riverhills Neuroscience
Cincinnati, Ohio, United States
University Neurology, Inc.
Cincinnati, Ohio, United States
Cleveland Clinic Center for Neurological Restoration
Cleveland, Ohio, United States
Capital Neurology Services & MS Institute
Gahanna, Ohio, United States
Neurological Associates of Tulsa
Tulsa, Oklahoma, United States
Columbia Pain Management, PC
Hood River, Oregon, United States
Allegheny General Hospital_Department of Neurology
Pittsburgh, Pennsylvania, United States
Coastal Neurology, PA
Port Royal, South Carolina, United States
Victorium Clinical Research
San Antonio, Texas, United States
Neurology Center of San Antonio
San Antonio, Texas, United States
Gershon Pain Specialists
Virginia Beach, Virginia, United States
Evergreen Hospital Medical Center/Booth Gardner Parkinson's Care Center
Kirkland, Washington, United States
South Puget Sound Neurology
Tacoma, Washington, United States
Gundersen Clinic, Ltd.
La Crosse, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Trosch RM, Misra VP, Maisonobe P, Om S. Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice. Clin Park Relat Disord. 2020 Jun 15;3:100063. doi: 10.1016/j.prdoa.2020.100063. eCollection 2020.
Espay AJ, Trosch R, Suarez G, Johnson J, Marchese D, Comella C. Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale. Parkinsonism Relat Disord. 2018 Jul;52:94-97. doi: 10.1016/j.parkreldis.2018.03.002. Epub 2018 Mar 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A-TL-52120-156
Identifier Type: -
Identifier Source: org_study_id